Literature DB >> 28473688

Long-Term Outcome of Liver Resection Versus Transplantation for Hepatocellular Carcinoma in a Region Where Living Donation is a Main Source.

Pil Soo Sung1, Hyun Yang1, Gun Hyung Na2, Seawon Hwang1, Donghoon Kang1, Jeong Won Jang3, Si Hyun Bae1, Jong Young Choi1, Dong Goo Kim2, Seung Kew Yoon1, Young Kyoung You2.   

Abstract

BACKGROUND The aim of this study was to define the best curative strategy in patients with hepatocellular carcinoma (HCC) in a hepatitis B virus (HBV)-endemic region where living donation dominates the type of cadaveric donation for liver transplantation (LT). MATERIAL AND METHODS A retrospective cohort comprised those patients whose clinical course could potentially be traced for at least 10 years. We found 262 HCC patients who had undergone curative surgical treatment from March 1997 to August 2006. Among these patients, 156 were treated with liver resection (LR) (R group) and 106 patients underwent LT (T group, 100 patients with living donor). Tumor characteristics, overall survival (OS), and recurrence-free survival (RFS) were analyzed. RESULTS Postoperative mortality was not significantly different between the groups, whereas recurrence rate during the study period (until August 2016) was higher in the R group (56% in the R group versus 19% in the T group, p<0.001). The 10-year and 15-year OS and RFS were better in the T group. Subgroup analysis with patients having solitary and £5 cm tumor by preoperative imaging showed that the 10-year and 15-year OS and RFS were much better in the T group, irrespective of their preoperative liver function defined by MELD score. In the T group, resection as the surgical procedure and tumor size on histology were poor prognostic factors for RFS. Importantly, this superiority of LT over LR in OS and RFS applied only to the patients with relatively low preoperative alpha-fetoprotein (AFP) levels (AFP <100 ng/mL), because patients with higher levels compared with lower levels of AFP tended to have more recurrent tumors after LT, but not in the case of LR during long-term follow-up. CONCLUSIONS Overall, LT was associated with better survival outcomes than resection in patients with HCC in Korea, where living donation is a main transplant source.

Entities:  

Mesh:

Year:  2017        PMID: 28473688     DOI: 10.12659/aot.904287

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  9 in total

1.  Prognosis of Hepatocellular Carcinoma Patients Who Achieved Long-Term Recurrence-Free Survival After Curative Therapy: Impact of the ALBI Grade.

Authors:  Hajime Matsushima; Yuko Takami; Tomoki Ryu; Munehiro Yoshitomi; Masaki Tateishi; Yoshiyuki Wada; Hideki Saitsu
Journal:  J Gastrointest Surg       Date:  2018-05-07       Impact factor: 3.452

2.  Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.

Authors:  Jin Hean Koh; Darren Jun Hao Tan; Yuki Ong; Wen Hui Lim; Cheng Han Ng; Phoebe Wen Lin Tay; Jie Ning Yong; Mark D Muthiah; Eunice X Tan; Ning Qi Pang; Beom Kyung Kim; Nicholas Syn; Alfred Kow; Brian K P Goh; Daniel Q Huang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 8.265

Review 3.  Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.

Authors:  Pil Soo Sung; Jeong Won Jang
Journal:  Int J Mol Sci       Date:  2018-11-19       Impact factor: 5.923

4.  Surgery strategy of 13 cases to control bleeding from the liver on laparoscopic repeat liver resection for recurrent hepatocellular carcinoma.

Authors:  Shuiping Yu; Tang Bo; Binzong Hou; Jiangfa Li; Xueling Zhou
Journal:  J Minim Access Surg       Date:  2019 Jul-Sep       Impact factor: 1.407

5.  Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma.

Authors:  Hyojin Chae; Pil Soo Sung; Hayoung Choi; Ahlm Kwon; Dain Kang; Yonggoo Kim; Myungshin Kim; Seung Kew Yoon
Journal:  Ann Lab Med       Date:  2021-03-01       Impact factor: 3.464

6.  Application of da Vinci robot and laparoscopy on repeat hepatocellular carcinoma.

Authors:  Shuiping Yu; Guandou Yuan; Shiliu Lu; Jiangfa Li; Bo Tang; Fudi Zhong; Huizhao Su; Songqin He
Journal:  J Minim Access Surg       Date:  2022 Jul-Sep       Impact factor: 1.018

7.  Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis.

Authors:  Jiansong Wu; Zhiwei Yin; Liuxia Cao; Xiaodan Xu; Tao Yan; Changting Liu; Diangeng Li
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

8.  Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment.

Authors:  Jongduk Kwon; Kwang-Sik Chun; In-Sang Song; Seok-Hwan Kim; Sunjong Han
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2020-02-27

9.  Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant.

Authors:  Pil Soo Sung; Ji Won Han; Changho Seo; Joseph Ahn; Soon Kyu Lee; Hee Chul Nam; Ho Joong Choi; Young Kyoung You; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon
Journal:  Front Pharmacol       Date:  2021-07-13       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.